Immuneering (NASDAQ:IMRX) said it has entered into a clinical supply agreement with Eli Lilly (NYSE:LLY) for its cancer drug olomorasib.
This agreement will facilitate the evaluation of Immuneering’s lead candidate, atebimetinib in combination with olomorasib.
The combination will be tested in a planned phase 2 clinical trial targeting patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer who have not responded to previous treatments.
This move comes after a trial deal between Immuneering and Regeneron Pharmaceuticals (REGN) in February to evaluate atebimetinib in combination with cemiplimab in patients with advanced non-small cell lung cancer.
Immuneering said it will retain global rights for the development and commercialization of atebimetinib.